| Fecha: |
2022 |
| Resumen: |
To understand the determinants of long-term immune responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the concurrent impact of vaccination and emerging variants, we follow a prospective cohort of 332 patients with coronavirus disease 2019 (COVID-19) over more than a year after symptom onset. We evaluate plasma-neutralizing activity using HIV-based pseudoviruses expressing the spike of different SARS-CoV-2 variants and analyze them longitudinally using mixed-effects models. Long-term neutralizing activity is stable beyond 1 year after infection in mild/asymptomatic and hospitalized participants. However, longitudinal models suggest that hospitalized individuals generate both short- and long-lived memory B cells, while the responses of non-hospitalized individuals are dominated by long-lived B cells. In both groups, vaccination boosts responses to natural infection. Long-term (. |
| Ayudas: |
Instituto de Salud Carlos III PI17/01518
Instituto de Salud Carlos III PI20/00093
Instituto de Salud Carlos III PI18/01332
|
| Derechos: |
Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades.  |
| Lengua: |
Anglès |
| Documento: |
Article ; recerca ; Versió publicada |
| Materia: |
B cell memory ;
Durability ;
Half-life ;
Humoral response ;
Neutralizing antibodies ;
Pseudovirus ;
SARS-CoV-2 ;
Severity ;
Variants of concern |
| Publicado en: |
Cell Reports Medicine, Vol. 3 (january 2022) , ISSN 2666-3791 |
visitante ::
identificación
(IrsiCaixa)
